BSE Live
Mar 25, 16:01Prev. Close
295.45
Open Price
301.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 25, 16:00Prev. Close
296.30
Open Price
297.50
Bid Price (Qty.)
306.15 (90)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Cohance Lifesciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 10.67 | 11.97 | 16.99 | 21.92 | 12.12 | |
| Diluted EPS (Rs.) | 10.62 | 11.97 | 16.99 | 21.92 | 12.12 | |
| Cash EPS (Rs.) | 12.92 | 13.89 | 18.68 | 23.46 | 13.37 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 90.95 | 80.76 | 68.72 | 59.74 | 41.84 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 90.95 | 80.76 | 68.72 | 59.74 | 41.84 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 6.00 | 5.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 42.95 | 40.26 | 52.25 | 51.86 | 39.66 | |
| PBDIT/Share (Rs.) | 16.36 | 18.27 | 24.65 | 30.16 | 17.86 | |
| PBIT/Share (Rs.) | 14.11 | 16.35 | 22.97 | 28.62 | 16.62 | |
| PBT/Share (Rs.) | 13.80 | 16.06 | 22.76 | 28.38 | 16.26 | |
| Net Profit/Share (Rs.) | 10.67 | 11.97 | 16.99 | 21.92 | 12.12 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 38.09 | 45.36 | 47.18 | 58.15 | 45.03 | |
| PBIT Margin (%) | 32.86 | 40.60 | 43.96 | 55.19 | 41.90 | |
| PBT Margin (%) | 32.13 | 39.88 | 43.56 | 54.72 | 40.99 | |
| Net Profit Margin (%) | 24.84 | 29.73 | 32.52 | 42.27 | 30.56 | |
| Return on Networth / Equity (%) | 11.73 | 14.82 | 24.72 | 36.70 | 28.97 | |
| Return on Capital Employed (%) | 15.13 | 19.49 | 32.41 | 45.65 | 37.14 | |
| Return on Assets (%) | 10.49 | 13.60 | 22.09 | 30.92 | 22.71 | |
| Total Debt/Equity (X) | 0.03 | 0.02 | 0.04 | 0.06 | 0.13 | |
| Asset Turnover Ratio (%) | 0.45 | 0.49 | 0.71 | 0.83 | 0.82 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.32 | 11.47 | 6.19 | 5.31 | 2.57 | |
| Quick Ratio (X) | 2.60 | 9.38 | 4.17 | 3.95 | 1.65 | |
| Inventory Turnover Ratio (X) | 5.84 | 0.93 | 1.42 | 1.90 | 1.65 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 47.07 | 18.24 | 8.24 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 42.83 | 17.05 | 7.48 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 52.93 | 81.76 | 91.76 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 57.17 | 82.95 | 92.52 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 29,575.89 | 17,240.86 | 12,056.22 | 15,793.47 | 12,742.82 | |
| EV/Net Operating Revenue (X) | 27.05 | 16.82 | 9.06 | 11.96 | 12.62 | |
| EV/EBITDA (X) | 71.00 | 37.08 | 19.21 | 20.57 | 28.02 | |
| MarketCap/Net Operating Revenue (X) | 27.00 | 16.80 | 9.05 | 11.92 | 12.49 | |
| Retention Ratios (%) | 0.00 | 0.00 | 52.92 | 81.75 | 91.75 | |
| Price/BV (X) | 12.75 | 8.38 | 6.88 | 10.34 | 11.84 | |
| Price/Net Operating Revenue | 27.00 | 16.80 | 9.05 | 11.92 | 12.49 | |
| Earnings Yield | 0.01 | 0.02 | 0.04 | 0.04 | 0.02 |
18.02.2026
BNP Paribas buys over Rs 54 crore worth shares in Capri Global Capital from Morgan Stanley
13.02.2026
04.12.2025
Cohance Life Consolidated September 2025 Net Sales at Rs 555.57 crore, up 115.57% Y-o-Y
27.11.2025
Cohance Life Standalone September 2025 Net Sales at Rs 497.79 crore, up 110.87% Y-o-Y
04.12.2025
Cohance Life Consolidated September 2025 Net Sales at Rs 555.57 crore, up 115.57% Y-o-Y
27.11.2025
Cohance Life Standalone September 2025 Net Sales at Rs 497.79 crore, up 110.87% Y-o-Y
12.06.2025
Cohance Life Standalone March 2025 Net Sales at Rs 330.17 crore, up 35.58% Y-o-Y
04.03.2025
Suven Pharma Consolidated December 2024 Net Sales at Rs 307.15 crore, up 39.73% Y-o-Y